Nuvectis Pharma
- Biotech or pharma, therapeutic R&D
Nuvectis Pharma (NVCT) oncology pipeline includes: 1) NXP800 - ongoing single single-agent clinical studies in patients with platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma; 2) NXP900, a next generation selective YES1/SRC kinase inhibitor in phase 1 with demonstrated pharmacodynamic activity in humans.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}